Candriam Equities L Oncology C EUR C
- ISIN
- LU1864484214
- Provider
- Candriam SCA
- Close Price
- €274.74 *
- Lipper Rating
- ESG Score
- Characteristics
- Sustainable
* Data as of 10 September 2026
Performance
Loading...
| Total | p.a. | |
|---|---|---|
| YTD | +7.94% | — |
| 1 Year | +29.29% | +29.29% |
| 3 Years | +24.98% | +7.71% |
| 5 Years | +15.82% | +2.98% |
Past performance is not a reliable indicator of future results. The value of an investment and the income from it can fall as well as rise.
Key Facts
| Asset Class | Equity |
| Holdings Classification | Equity United States Multi-Cap Core |
| Geographical Focus | Global |
| Fund Size | €1,525,299,234 |
| Total Expense Ratio | 1.95% |
| Currency | EUR |
| Domicile | LU |
| Managementstyle | Active |
| SFDR Article | Article 9 |
Available in
Liechtenstein Life InvestLiechtenstein Life PensionLiechtenstein Life WealthProsperity PlusVWL-Förderkonzept für Bundeswehrangehörigebest value rentvalue invest VWLvalue rent business UK
Country Exposure
United States
67.6%
Switzerland
13.1%
United Kingdom
5.8%
Germany
5.6%
Denmark
2.2%
Other
5.8%
Description
The fund seeks to achieve capital growth by investing in the principal assets traded and to outperform the benchmark while also generating a positive social impact over the long term, by selecting companies that address certain societal challenges and mobilise resources in the fight against cancer. ...